Physician profile
Steven J Smith
NPI 1881687457
$9,283.84
in general payments reported to CMS, 2019-2025
30 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $775 · 2021: $1,583 · 2022: $1,636 · 2023: $1,317 · 2024: $1,626 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,220.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,286.35 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,610.11 | 2019-2025 | |
| Genzyme Corporation | $1,051.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $595.65 | 2020-2024 | Dupixent |
| Janssen Biotech, INC. | $552.28 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $545.37 | 2019-2025 | Ilumya |
| Amgen INC. | $378.44 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $329.66 | 2020-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $315.40 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.64 | 2023-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $204.02 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $160.75 | 2020-2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.92 | 2019-2023 | Duobrii, Arazlo, Jublia |
| Incyte Corporation | $130.69 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $127.76 | 2019-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Pfizer INC. | $89.60 | 2020-2022 | |
| Revance Therapeutics, INC. | $68.36 | 2024 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $63.15 | 2024-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $38.62 | 2020 | |
| Epi Health, LLC | $35.86 | 2019-2022 | |
| Springworks Therapeutics, INC. | $33.08 | 2025 | Gomekli |
| Dermira, INC. | $24.44 | 2020 | |
| Almirall LLC | $23.01 | 2021 | |
| Mayne Pharma Commercial LLC | $17.79 | 2020 | |
| Sebela Pharmaceuticals INC. | $15.06 | 2019 | |
| Fidia Pharma USA INC. | $14.43 | 2024 | |
| Arcutis Biotherapeutics, INC. | $14.03 | 2024 | Zoryve |
| Convatec INC. | $13.55 | 2024 | |
| Allergan, INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.